Brought to you by 
BMS, QDose end inhaled insulin product deal
Sep 2003
Executive Summary
QDose has licensed Bristol-Myers Squibb worldwide exclusive rights to its breath-activated, inhaled insulin product candidate. QDose is a JV owned by drug delivery company MicroDose Technologies and Quadrant Drug Delivery Ltd. (QDD; dry powder pulmonary delivery), the July 2003 management buyout of the former Elan Drug Delivery Ltd.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, QDose end inhaled insulin product deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice